🧪FDA Announces Public Meeting on Biosimilar User Fee Act III
Biosimilar User Fee Act III Regulatory Science Program Interim Public Meeting; Public Meeting; Interim Report; Availability; Request for Comments
Summary
The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public meeting entitled "Biosimilar User Fee Act (BsUFA) III Regulatory Science Program Interim Public Meeting" and the availability of the report entitled "BsUFA III Regulatory Science Pilot Program Interim Report." The purpose of the public meeting is to review the progress of the BsUFA III Regulatory Science Program aims, or demonstration projects, and to solicit input on future research priorities. Under the BsUFA reauthorization commitment letter for fiscal years (FYs) 2023 through 2027 (BsUFA III), FDA committed to piloting a regulatory science program to facilitate biosimilar and interchangeable product development that focuses on: (1) advancing the development of interchangeable products; and (2) improving the efficiency of biosimilar product development. The purpose of the interim progress report is to provide a summary of activities that established the pilot program, an overview of research progress, and a brief discussion of future directions.
Agencies
- Health and Human Services Department
- Food and Drug Administration
Business Impact
$$ - Med
The text discusses the FDA's public meeting and pilot program under the Biosimilar User Fee Act III, which affects biosimilar development efficiency and interchangeability. This has significant regulatory implications for businesses in the pharmaceutical and biotech sectors, impacting compliance and potential research priorities.